Literature DB >> 2494569

Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction.

M R Filling-Katz1, H F Merrick, J K Fink, R B Miles, J Sokol, N W Barton.   

Abstract

Seven patients with Fabry's disease and severe pain received carbamazepine (CMZ). Five of 7 patients had moderate to complete relief based upon self-assessment of pain levels. Preexisting autonomic dysfunction was exacerbated by CMZ in 2. Complications encountered were ileus, urinary retention, and gastrointestinal disturbance. Although CMZ was useful in treatment of pain, caution should be employed in this disease.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2494569     DOI： 10.1212/wnl.39.4.598

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  13 in total

1.  Anderson-Fabry disease in Austria.

Authors:  Matthias Lorenz; Anna-Christina Hauser; Margot Püspök-Schwarz; Peter Kotanko; Ingrid Arias; Herbert Zodl; Reinhard Kramar; Eduard Paschke; Till Voigtländer; Gere Sunder-Plassmann
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

Review 2.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

3.  Carbamazepine-induced urinary retention.

Authors:  Houssem Hmouda; Chaker Ben Salem; Mounir Grira; Raoudha Slim; Kamel Bouraoui
Journal:  Br J Clin Pharmacol       Date:  2007-12       Impact factor: 4.335

4.  Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.

Authors:  Gabor E Linthorst; Alessandro P Burlina; Franco Cecchi; Timothy M Cox; Janice M Fletcher; Ulla Feldt-Rasmussen; Roberto Giugliani; Carla E M Hollak; Gunnar Houge; Derralynn Hughes; Iikka Kantola; Robin Lachmann; Monica Lopez; Alberto Ortiz; Rossella Parini; Alberto Rivera; Arndt Rolfs; Uma Ramaswami; Einar Svarstad; Camilla Tondel; Anna Tylki-Szymanska; Bojan Vujkovac; Steven Waldek; Michael West; F Weidemann; Atul Mehta
Journal:  JIMD Rep       Date:  2012-07-14

Review 5.  [Fabry disease : diagnosis and treatment].

Authors:  N Üçeyler; C Sommer
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

6.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

Review 7.  [Pain therapy for Fabry's disease].

Authors:  C Sommer; N Uçeyler; T Duning; K Arning; R Baron; E Brand; S Canaan-Kühl; M Hilz; D Naleschinski; C Wanner; F Weidemann
Journal:  Internist (Berl)       Date:  2013-01       Impact factor: 0.743

8.  Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.

Authors:  Alessandro Salviati; Alessandro P Burlina; Walter Borsini
Journal:  Neurol Sci       Date:  2010-03-19       Impact factor: 3.307

Review 9.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

Review 10.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.